EuBiologics Co., Ltd. (KOSDAQ:206650)

South Korea flag South Korea · Delayed Price · Currency is KRW
13,410
-40 (-0.30%)
Jul 18, 2025, 3:30 PM KST
21.69%
Market Cap491.13B
Revenue (ttm)69.37B
Net Income (ttm)-13.88B
Shares Out36.62M
EPS (ttm)-381.00
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume169,569
Average Volume168,380
Open13,450
Previous Close13,450
Day's Range13,350 - 13,620
52-Week Range9,350 - 18,800
Beta1.48
RSI62.14
Earnings DateMay 9, 2025

About EuBiologics

EuBiologics Co., Ltd., a biopharmaceutical company, provides vaccines for epidemics in South Korea. It offers Euvichol Plus, an oral cholera prevention vaccine; and rCRM197, a diphtheria toxoid vaccine. The company also provides EcML, a vaccine for cell membrane, as well as offers COVID-19 diagnostic kits. In addition, it offers CMO services comprising of drug product production, cell bank production, drug product production, and drug substance production. Further, the company provides CRMO services, including production process development, fo... [Read more]

Sector Healthcare
Founded 2010
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 206650
Full Company Profile

Financial Performance

In 2023, EuBiologics's revenue was 69.37 billion, an increase of 25.06% compared to the previous year's 55.47 billion. Losses were -13.88 billion, 1163.0% more than in 2022.

Financial Statements

News

There is no news available yet.